Creating new treatments for stimulant use disorder
Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder
This study is testing a new medication called SBS-518 that aims to help people struggling with stimulant use disorder, like those using methamphetamine or cocaine, by reducing their cravings without giving them a high, and there may be chances for patients to join early trials as the research moves forward.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project ID | NIH-10897743 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication, SBS-518, aimed at treating stimulant use disorder (StUD), which affects millions of people in the U.S. The approach involves targeting specific brain receptors to reduce the urge to use stimulants like methamphetamine and cocaine without causing rewarding effects. The research will include optimizing the lead compound and conducting necessary safety studies before moving towards clinical trials. Patients may have the opportunity to participate in early-stage trials as the treatment progresses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with stimulant use disorder who are seeking treatment options.
Not a fit: Patients who are not struggling with stimulant use disorder or those who have not responded to previous stimulant treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed pharmacotherapy for individuals struggling with stimulant use disorder.
How similar studies have performed: While stimulant use disorder treatment is an emerging field, this approach is novel as there are currently no FDA-approved medications specifically for StUD.
Where this research is happening
New York City, United States
- Sparian Biosciences, INC. — New York City, United States (Active)
Researchers
- Principal investigator: Reich, Jeffrey — Sparian Biosciences, INC.
- Study coordinator: Reich, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.